CAMBRIDGE, Mass.--(BUSINESS WIRE)--Iterative Health, a technology and services company dedicated to advancing gastrointestinal care, will present new data at the American College of Gastroenterology 2024 Annual Meeting, co-authored with leading academic researchers and life science partners. The five abstracts highlight the opportunity for advanced machine learning (ML) algorithms to address shortcomings in the current approach to endoscopic assessment of inflammatory bowel disease (IBD) in clinical trials and routine care.
“There is a clear need to innovate traditional endoscopic assessments used in gastrointestinal research to improve the accuracy of efficacy measurements in clinical trials,” said Dr. David T. Rubin, Director of the Inflammatory Bowel Disease Center at the University of Chicago Medicine. “Our ongoing research with Iterative Health shows the immense potential of their machine learning tools to refine endoscopic assessments and thereby enhance the drug development process, ultimately improving long-term patient outcomes.”
The studies presented at ACG will demonstrate the potential of ML applications to address the gaps in the current approach to endoscopic assessment in IBD research, with a focus on ulcerative colitis. The collection of abstracts includes a first-of-its-kind comparison of two ML models and an overview of a novel real-world dataset linking AI-assessed endoscopic disease severity to electronic health records (EHR) data.
“Given the complexities in conducting GI trials, there is a significant opportunity to use technology to drive more effective and efficient clinical studies that generate deeper insights into disease activity,” said Dr. Vijay Yajnik, Vice President, Head of Gastroenterology, US Medical Affairs, Takeda. “The goal of our partnership with Iterative Health is to facilitate more evidence-based decision-making on therapy utilization in the real world, and ultimately get a step closer to precision medicine in IBD.”
By harnessing advanced technology and data analytics, Iterative Health is streamlining GI research to support drug development and post-marketing strategies. This approach aims to provide more objective measures of disease severity and treatment response, enhancing the efficiency and accuracy of clinical research.
"At Iterative Health, we are leveraging a scientific approach to show how machine learning can transform research and development of new therapies,” said Dr. Shrujal Baxi, MPH, Chief Medical Officer at Iterative Health. “We are focused on evolving traditional endpoints, such as endoscopic scoring, to deliver new, actionable insights. Collaborating with our industry partners to produce and present new data is a key step in our long-term strategy to shift the paradigm in evidence generation for GI diseases.”
For more information on Iterative Health’s presentations at ACG 2024, visit https://acgmeetings.gi.org/.
About Iterative Health
Iterative Health is a healthcare technology and services company on a mission to provide timely access to a higher standard of gastroenterology care. With deep expertise in artificial intelligence and clinical research, we empower healthcare professionals to provide consistently high-quality colorectal cancer screenings and support clinical research teams and study sponsors to expand and accelerate patient access to novel therapeutics. The company is based in Cambridge, Massachusetts, with offices across the United States. For more information, visit www.iterative.health and follow us on LinkedIn, X for the latest company updates.
